Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14483511 | 0.99 | DPP4 (0.51) | DPP4SLC6A4SLC6A3DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL14483510 | 0.99 | DPP4 (0.51) | DPP4SLC6A4SLC6A3DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL14483508 | 0.99 | DPP4 (0.51) | DPP4SLC6A4SLC6A3DPP8DPP9 | |
| SCHEMBL14549853 | 0.84 | DPP4 (0.54) | DPP4SLC6A4SLC6A3DPP8DPP9 | |
| SCHEMBL8188146 | 0.84 | DPP4 (0.54) | DPP4SLC6A4SLC6A3DPP8DPP9 | |
| SCHEMBL14549848 | 0.84 | DPP4 (0.54) | DPP4SLC6A4SLC6A3DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL14483002 | 0.83 | DPP4 (0.53) | DPP4SLC6A4SLC6A3DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL14483006 | 0.83 | DPP4 (0.53) | DPP4SLC6A4SLC6A3DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL14483003 | 0.83 | DPP4 (0.53) | DPP4SLC6A4SLC6A3DPP8DPP9 | |
| SCHEMBL14549842 | 0.83 | DPP4 (0.60) | DPP4SLC6A4SLC6A3DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012485-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-10 | — | — | US | disclosed |
| US-20130012485-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-10 | — | — | US | disclosed |
| WO-2008077597-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012485-A1 | ORGANIC COMPOUNDS | DPP4, DPP3, DPP7 | DPP4 1/4885SLC6A4 461/4885SLC6A3 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.